review˜The œNephron journals/Nephron journalsJan 1, 2016Closed access

Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?

AAAimun AhmedTJTom JornaSBSunil Bhandari

Royal Preston Hospital · Hull and East Yorkshire Hospitals NHS Trust · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Chronic kidney disease (CKD) is a worldwide public health problem associated with a high prevalence of cardiovascular disease (CVD) and impaired quality of life. Previous research for preventing loss of glomerular filtration rate (GFR) has focused on reducing blood pressure (BP) and proteinuria. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (ARB) are commonly used in patients with early CKD, but their value in advanced CKD (estimated GFR (eGFR) ≤30 ml/min/1.73 m2) is unknown. There remains a debate about the omission of ACEi/ARB in patients with advanced CKD and their use in association with CVD or heart failure. Does the potential gain in eGFR with ACEi/ARB cessation…

Citation impact

11,735
total citations
FWCI
801.52
Percentile
100%
References
174
Citations per year

Authors

3

Topics & keywords

Topics
Keywords
  • Medicine
  • Renal function
  • Kidney disease
  • Internal medicine
  • Blood pressure
  • Angiotensin-converting enzyme
  • Angiotensin Receptor Blockers
  • Proteinuria
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding